PLoS Genetics (Apr 2014)

The RNA-binding protein QKI suppresses cancer-associated aberrant splicing.

  • Feng-Yang Zong,
  • Xing Fu,
  • Wen-Juan Wei,
  • Ya-Ge Luo,
  • Monika Heiner,
  • Li-Juan Cao,
  • Zhaoyuan Fang,
  • Rong Fang,
  • Daru Lu,
  • Hongbin Ji,
  • Jingyi Hui

DOI
https://doi.org/10.1371/journal.pgen.1004289
Journal volume & issue
Vol. 10, no. 4
p. e1004289

Abstract

Read online

Lung cancer is the leading cause of cancer-related death worldwide. Aberrant splicing has been implicated in lung tumorigenesis. However, the functional links between splicing regulation and lung cancer are not well understood. Here we identify the RNA-binding protein QKI as a key regulator of alternative splicing in lung cancer. We show that QKI is frequently down-regulated in lung cancer, and its down-regulation is significantly associated with a poorer prognosis. QKI-5 inhibits the proliferation and transformation of lung cancer cells both in vitro and in vivo. Our results demonstrate that QKI-5 regulates the alternative splicing of NUMB via binding to two RNA elements in its pre-mRNA, which in turn suppresses cell proliferation and prevents the activation of the Notch signaling pathway. We further show that QKI-5 inhibits splicing by selectively competing with a core splicing factor SF1 for binding to the branchpoint sequence. Taken together, our data reveal QKI as a critical regulator of splicing in lung cancer and suggest a novel tumor suppression mechanism involving QKI-mediated regulation of the Notch signaling pathway.